Key Highlights

  • Co-Diagnostics (NASDAQ:CODX) was quoted at USD 0.4130 pre-market on Tuesday, November 10, 2026, a 29.47% gain on a calculated Monday close of USD 0.3190.
  • Published data showed a Market Value of USD 4.78 million across 6.25 million shares at USD 0.7645 on October 14, 2026, which puts the pre-market price about 46% lower (calculated).
  • Trailing 12-month Revenue reached USD 721,386 against a net loss of USD 47.06 million, with cash of USD 3.65 million and total Debt of USD 1.80 million.
  • The 20-day average Volume was 359,681 shares and the 52-week price change stood at -93.38%, so the stock trades in a thin range after a deep sell-off.

What Drove the Co-Diagnostics Pre-Market Move (+29.47%)

Co-Diagnostics is a molecular diagnostics firm based in Utah, trading on Nasdaq. The pre-market reading on November 10, 2026 came in at USD 0.4130, up 29.47%. Working backwards gives a calculated prior close of USD 0.3190, meaning Monday's session finished roughly 58% under the October 14 close of USD 0.7645 (calculated). Applying the pre-market price to the 6.25 million shares in published data implies a market value near USD 2.58 million (calculated), compared with USD 4.78 million at the October close. Multiplying the 20-day average of 359,681 shares by the pre-market price gives daily turnover of about USD 0.15 million (calculated). The bounce therefore follows a sharp fall, and a recovery from USD 0.3190 is still well short of the October level. A quote below USD 0.50 means each USD 0.01 tick is more than 2% of the price, so spreads are proportionally wide and small orders can move the print.

Why No Catalyst Has Been Confirmed

Searches surfaced third-quarter 2026 earnings-date notices and SEC filings, but no release dated November 9 or November 10, 2026 containing results or deal terms. No trigger appears in the published coverage. For context only, diagnostics small caps tend to move on quarterly figures, grant or contract wins, cash-runway updates, financing, or a Nasdaq minimum-bid notice, since a share price under USD 1.00 for 30 consecutive Business days can prompt a deficiency letter. A rebound after a steep fall can also happen without news, as short sellers cover or buyers step into a light order book. None of this is confirmed for Co-Diagnostics (NASDAQ:CODX).

Valuation, Liquidity and Risks

At USD 0.4130 the shares sit below the USD 1.00 Nasdaq minimum-bid threshold, which raises the odds of a reverse split or a compliance process. Cash of USD 3.65 million set against a trailing net loss of USD 47.06 million, which may include non-cash items, suggests a short runway unless new funding arrives, and dilution would reduce per-share value. Revenue of USD 721,386 is tiny beside the loss. The 52-week change of -93.38% shows how much value has been wiped out. Pre-market volume is light, spreads are wide, and the move could reverse at the open. Nothing here implies Co-Diagnostics (NASDAQ:CODX) will keep rising. Earnings, grant news and financing terms should each be checked directly in company filings before drawing any conclusion about the next session or the balance sheet.

Where Things Stand

The most direct answer to why Co-Diagnostics (NASDAQ:CODX) is up 29.47% pre-market is that no catalyst has been identified in the available coverage. The USD 0.4130 quote sits on a calculated prior close of USD 0.3190 and beneath the October close of USD 0.7645. With USD 3.65 million in cash, a USD 47.06 million trailing loss and a share price below USD 1.00, dilution and listing risk remain central. Australian readers should note that every figure here is in US dollars.